| Stephanie A Mccardle, MD | |
|
1411 S Green St, Suite 130, Brownsburg, IN 46112-2049 | |
| (317) 858-4610 | |
| (317) 858-4620 |
| Full Name | Stephanie A Mccardle |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 1411 S Green St, Brownsburg, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053342543 | NPI | - | NPPES |
| 200865320 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01048990 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alpha Transitional Care Llc | Indianapolis, IN | Hospice |
| Brownsburg Meadows | Brownsburg, IN | Nursing home |
| Waters Of Lebanon, The | Lebanon, IN | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Osh-in Physicians Group Pc | 6800100512 | 55 |
News Archive
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
Deaths caused by indirect effects of the pandemic emphasize the need for policy changes that address widening health and racial inequities.
Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns.
› Verified 8 days ago
| Entity Name | Arm Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992131049 PECOS PAC ID: 8729214887 Enrollment ID: O20131119000908 |
News Archive
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
Deaths caused by indirect effects of the pandemic emphasize the need for policy changes that address widening health and racial inequities.
Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns.
› Verified 8 days ago
| Entity Name | Osh-in Physicians Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073995338 PECOS PAC ID: 6800100512 Enrollment ID: O20150807014284 |
News Archive
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
Deaths caused by indirect effects of the pandemic emphasize the need for policy changes that address widening health and racial inequities.
Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie A Mccardle, MD 1100 Southfield Dr, Suite 1370, Plainfield, IN 46168-4498 Ph: (317) 837-5570 | Stephanie A Mccardle, MD 1411 S Green St, Suite 130, Brownsburg, IN 46112-2049 Ph: (317) 858-4610 |
News Archive
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
Deaths caused by indirect effects of the pandemic emphasize the need for policy changes that address widening health and racial inequities.
Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns.
› Verified 8 days ago
David Bain, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5492 N Ronald Reagan Pkwy Ste 250, Brownsburg, IN 46112 Phone: 317-852-3851 Fax: 317-852-1246 | |
Mark P Schopper, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1411 S Green St, Suite 130, Brownsburg, IN 46112 Phone: 317-858-4610 Fax: 317-858-4620 | |
Stacia L Groover Maltby, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1411 S Green St, Suite 130, Brownsburg, IN 46112 Phone: 317-858-4610 Fax: 317-858-4620 | |
Dr. David E Wilmot, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1411 S Green St, Suite 130, Brownsburg, IN 46112 Phone: 317-858-4610 Fax: 317-858-4620 | |
Michael Steven Pizzato, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 321 E Northfield Dr, Suite 100, Brownsburg, IN 46112 Phone: 317-852-6065 Fax: 317-852-2468 | |
Allison Suzanne Foley, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1411 S Green St, Brownsburg, IN 46112 Phone: 317-852-7700 |